Vertex, Inc.
No SEC Form 4 filings for $VERX in the last 30 days.
See all $VERX insider activity →Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.
Simply Wall St reports Vertex (VERX) shares fell about 8% to $12.39 after Q2 results. Revenue rose to about $204m and the company swung to profit, with basic EPS of $0.06 and adjusted EBITDA of $51m (25% margin). Cloud and e-invoicing growth guidance and execution concerns left investors divided.
Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.
Over the past 7 days, alphai's AI scored 8 news stories mentioning VERX (Vertex, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 3 bearish.
Recent VERX coverage spans earnings, market movers and financial news.
Raised EBITDA and cloud-growth outlook, but slower cloud-conversion pace and longer sales cycles temper near-term confidence.
Q2 delivered earnings leverage (profit swing, higher adjusted EBITDA margin), yet investors focused on slower cloud migrations and deal slippage, driving a sharp selloff.
The selloff is driven by forward growth and cash-flow concerns despite a headline EPS and revenue beat.
Cloud growth miss and lowered FY26 guidance are driving negative sentiment and likely near-term multiple compression for VERX.
The key tradable item is the Q3 sales guide coming in below market estimates, which can pressure near-term expectations despite the Q2 beat.
alphai scores every news story that mentions VERX with an AI model for sentiment and relevance, and aggregates insider trades from Vertex, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.
6 min readSimply Wall St reports Vertex (VERX) shares fell about 8% to $12.39 after Q2 results. Revenue rose to about $204m and the company swung to profit, with basic EPS of $0.06 and adjusted EBITDA of $51m (25% margin). Cloud and e-invoicing growth guidance and execution concerns left investors divided.
4 min readVertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.
4 min readVertex Inc. (NASDAQ:VERX) shares dropped 13.2% after its Q2 results missed cloud growth expectations and analysts cut price targets. DA Davidson lowered its target to $12 from $15, citing slower cloud conversions and reduced FY26 cloud growth guidance to 18% from 25%. Other analysts also adjusted targets following guidance and deal-cycle comments.
3 min readVertex Inc (NASDAQ:VERX) reported Q2 EPS of $0.20, above the $0.19 consensus, and sales of $203.97 million, above $202.30 million. For Q3, it guided revenue of $208.0 million to $211.0 million versus $211.70 million expected. Shares fell about 2% to $13.13 premarket as analysts lowered forecasts and adjusted price targets.
2 min readVertex Inc. (NASDAQ: VERX) said it added Chatelle Lynch as Chief People Officer, Carlos Mercuriali as SVP and Europe Regional Manager, and Bala Chandran as Chief Product and Technology Officer. The company cited experience from The RealReal, McAfee, Avalara, Amazon, and Oracle, aiming to support global growth, SaaS transformation, and AI-first product development.
2 min readVertex, Inc. (NASDAQ: VERX) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenue rose 10.5% to $204.0 million, with software subscription revenue up 10.7% to $174.8 million and cloud revenue up 17.9% to $101.7 million. Adjusted EBITDA increased to $51.0 million. Outlook: Q3 revenue $208.0-$211.0 million and adjusted EBITDA $55.0-$57.0 million; FY 2026 revenue $825.0-$830.0 million and adjusted EBITDA $206.0-$210.0 million.
7 min readVertex, Inc. (VERX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 verx-20260803xex99d1.htm EX-99.1 Exhibit 99.1 Vertex Announces Second Quarter 2026 Financial Results KING OF PRUSSIA, PA – August 3, 2026: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, tod
6 min readCiti named its top picks in the US application software sector, citing near-term catalysts and risks for four companies into H2 2025. It ranked BILL Holdings (BL) highest on improving partner trends and sales execution, Workday (WK) positive on platform strategy, Intapp (INTA) more cautious on FY27 guidance, and Vertex (VERX) with estimate risk. The article also notes recent earnings and analyst rating changes.
4 min readVertex, Inc. (VERX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. VERTEX, INC._ June 10, 2026 0001806837 false 0001806837 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earlies
2 min read